Sg3 Management, LLC Alnylam Pharmaceuticals, Inc. Call Options Transaction History

Sg3 Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $5 Million - $7.03 Million	-41,500 Reduced 89.25%	5,000 $729,000
Q4 2021 Feb 15, 2022	BUY	$159.56 - $209.29 $2.38 Million - $3.12 Million	14,900 Added 47.15%	46,500 $7.89 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $3.24 Million - $3.97 Million	19,100 Added 152.8%	31,600 $5.97 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $1.59 Million - $2.2 Million	12,500 New	12,500 $1.77 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $1.23 Million - $1.47 Million	-10,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $1.21 Million - $1.65 Million	10,000 New	10,000 $1.46 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.